ResMed, Inc. is dedicated to developing and promoting products for the diagnosis and management of respiratory diseases, with a particular focus on sleep-disordered breathing.
The company's net sales come primarily from three product families: medical devices (50.4% of sales), masks (37.9% of sales), and software as a service (11.7% of sales).
ResMed operates six production facilities in the United States, Australia, China, Singapore, and Malaysia.
The United States is a significant market for the company, accounting for 61.4% of its total net sales.
UBS has a neutral stance on ResMed, reflecting caution about the company's performance in the competitive healthcare sector.